Pharmaceutical

Sandoz partners with Samsung Bioepis to license Stelara biosimilar

The agreement allows Sandoz exclusive marketing rights for the inflammatory bowel disease therapy in Europe and North America.

Sep 11, 2023 - 20:00
Sandoz partners with Samsung Bioepis to license Stelara biosimilar
The agreement allows Sandoz exclusive marketing rights for the inflammatory bowel disease therapy in Europe and North America.
Read the original article

Tags:

Previous Article

STAT+: Crinetics acromegaly drug succeeds in late-stage trial but would face sti...

Next Article

Pharmaceutical Technology Excellence Awards 2023: Viedoc

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Alzheimer’s drug approvals show we need a reevaluation of patient advocacy

Opinion: Alzheimer’s drug approvals show we need a reev...

Dec 19, 2023

UK pharma industry hits out at plans to rework statutory payment scheme

UK pharma industry hits out at plans to rework statutor...

Oct 9, 2023

Candor on gene therapy, Abiomed is warned, & BTK success in MS

Candor on gene therapy, Abiomed is warned, & BTK succes...

Oct 16, 2023